The Metastatic Cancer Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Metastatic Cancer Drugs Market:
https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report
According to The Business Research Company’s Metastatic Cancer Drugs Global Market Report 2024, The metastatic cancer drugs market size has grown steadily in recent years. It will grow from $55.28 billion in 2023 to $57.68 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to chemotherapy development, advancements in targeted therapies, immunotherapy discoveries, clinical trials success, improved diagnosis and staging.
The metastatic cancer drugs market size is expected to see steady growth in the next few years. It will grow to $69.46 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to precision medicine evolution, biomarker-driven therapies, liquid biopsy advancements, patient-centric approaches, comprehensive genomic profiling. Major trends in the forecast period include emerging combination therapies, nanomedicine advancements, long-term survivorship support, early intervention strategies, health equity and access .
The increasing prevalence of metastatic cancers is expected to propel the growth of the metastatic cancer drugs market going forward. Metastatic cancer refers to an advanced stage of cancer that spreads to other body parts. The number of cases of metastatic cancer rises, this leads to the development of novel cancer medications for treating various types of metastatic cancer. Furthermore, the rising cancer rate has increased the occurrence of metastatic cancers. For instance, according to the Journal of the national cancer institute published in 2022, the number of people living with metastatic breast, prostate, lung, colorectal, or bladder cancer or metastatic melanoma in the United States is expected to be 0.69 million cases by the year 2025. Furthermore, In April 2022, Breast cancer surpassed lung cancer to become the most diagnosed cancer worldwide, affecting an estimated 2.3 million women in 2021 alone, according to the Breast Cancer Research Foundation, a US-based not-for-profit organization in breast cancer for clinical and translational research. In the United States, where breast cancer has been the most frequent cancer for many years, 281,550 women are expected to be diagnosed in 2021. The predicted number of American women living with metastatic breast cancer has also increased to 168,000 this year, up from 155,000 last year. Therefore, the increasing prevalence of metastatic cancers drives the metastatic cancer drugs market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=11941&type=smp
The metastatic cancer drugs market covered in this report is segmented –
1) By Drug Class: HER2 Inhibitors, Immune Checkpoints Inhibitors, PARP Inhibitors, Kinase Inhibitors, Other Drug Class
2) By Cancer: Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, Other Cancers
3) By Treatment: Chemotherapy, Immunotherapy, Hormonal Therapy, Surgery, Other Treatments
4) By Route Of Administration: Intravenous, Intramuscular, Oral, Other Routes Of Administration
5) By End-Users: Hospitals, Specialty Clinics, Other End-Users
Product innovations have emerged as a key trend gaining popularity in the metastatic cancer drugs market. Major market players are concentrating their efforts on developing novel drugs to strengthen their position in the market. For instance, in January 2021, Daiichi Sankyo Company Limited a Japan-based pharmaceutical company, and AstraZeneca plc a British-Swedish pharmaceutical and biotechnology company were granted conditional approval in the European Union for the drug ENHERTU (trastuzumab deruxtecan) as a monotherapy for the treatment of HER2 positive metastatic breast cancer. The drug ENHERTU is considered a novel medicine to be approved for breast cancer in Europe with phase 2 single-arm data. This product is transforming the outcomes of patients suffering from HER2-positive metastatic breast cancer in the USA and Japan, and this approval in the EU will also enable to have greater benefits for this medicine to patients in the EU as well owing to the rising cases of cancers.
The metastatic cancer drugs market report table of contents includes:
1. Executive Summary
2.Metastatic Cancer Drugs Market Characteristics
3.Metastatic Cancer Drugs Market Trends And Strategies
4.Metastatic Cancer Drugs market analysis
5.Metastatic Cancer Drugs Market Size And Growth
6.Metastatic Cancer Drugs Segmentation
7.Metastatic Cancer Drugs Regional And Country Analysis
.
.
.
27.Metastatic Cancer Drugs Competitive Landscape And Company Profiles
28.Metastatic Cancer Drugs Key Mergers And Acquisitions
29.Metastatic Cancer Drugs Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Pfizer Inc.
- Johnson and Johnson Services Inc.
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
- AstraZeneca PLC
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
